Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients.

ABSTRACT:

Background

Selecting patients for early clinical trials is a challenging process and clinicians lack sufficient tools to predict overall survival (OS). Circulating cell-free DNA (cfDNA) has recently been shown to be a promising prognostic biomarker. The aim of this study was to investigate whether baseline cfDNA measurement could improve the prognostic information of the Royal Marsden Hospital (RMH) score.

Methods

Solid tumour patients referred for phase I trials were included in the Copenhagen Personalized Oncology (CoPPO) programme. Baseline characteristics were collected prospectively, including the RMH prognostic score, Eastern Cooperative Oncology Group (ECOG) performance status and concentration of cfDNA per millilitre plasma. Cox proportional hazards model was used to

SUBMITTER: Viller Tuxen I 

PROVIDER: S-EPMC6738043 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature